Depletion of ovarian reserve in young women after treatment for cancer in childhood: Detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound

Human Reproduction

Volumn 18, Issue 11, 2003, Pages 2368-2374

  Bath, L E ^a   Wallace, W H B ^a   Shaw, M P ^a   Fitzpatrick, C ^a   Anderson, R A ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b MRC Reproductive Biology Unit   (United Kingdom)

Author keywords

Anti M llerian hormone; Antral follicle count; Chemotherapy; Inhibin B; Ovarian reserve

Indexed keywords

ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; ETHINYLESTRADIOL; FOLLITROPIN; INHIBIN B; MUELLERIAN INHIBITING FACTOR; ORAL CONTRACEPTIVE AGENT; RECOMBINANT FOLLITROPIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; EWING SARCOMA; FEMALE; FOLLITROPIN BLOOD LEVEL; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; MEDULLOBLASTOMA; MENSTRUAL CYCLE; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVARY DISEASE; RHABDOMYOSARCOMA; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

FALLOPIA;

EID: 0242438564     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deg473     Document Type: Article

References (40)

1. Ahmed Eddiary, N.A., Lenton, E.A. and Cooke, I.D. (1994) Hypothalamic-pituitary ageing: Progressive increase in FSH and LH concentrations throughout the reproductive life in regularly menstruating women. Clin. Endocrinol., 41, 199-206.
2. Baarends, W.M., Uilenbroek, J.T., Kramer, P., Hoogerbrugge, J.W., Van Leeuwen, E.C., Themmen, A.P. et al. (1995) Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during post natal development, the estrous cycle, and gonadotrophin induced follicle growth. Endocrinology, 136, 4951-4962.
3. Bancsi, L.F., Broekmans, F.J., Eijkemans, M.J., De Jong, F.H., Habbema, JD. and Te Velde, E.R. (2002) Predictors of poor ovarian response in vitro fertilization: A prospective study comparing basal markers of ovarian reserve. Fertil. Steril., 77, 328-336.
4. Bath, L.E., Critchley, H.O.D., Chambers, S.E., Anderson, R.A., Kelnar, C.J. and Wallace, W.H.B. (1999) Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: Response to sex steroid replacement. Br. J. Obstet. Gynecol., 106, 1265-1272.
5. Bath, L.E., Anderson, R.A., Critchley, H.O.D., Kelnar, C.J.K. and Wallace, W.H.B. (2001) Hypothalamic-pituitary-ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia. Hum. Reprod., 16, 1838-1844.
6. Bath, L.E., Wallace, W.H.B. and Critchley, H.O.D. (2002) Late effects of treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. Br. J. Obstet. Gynaecol., 109, 107-114.
7. Byrne, J. (1999) Infertility and premature menopause in childhood cancer survivors. Med. Pediatr. Oncol., 33, 24-28.
8. Byrne, J., Fears, T.R., Gail, M.H., Pee, D., Connelly, R.R., Austin, D.F., Holmes, G.F., Holmes, F.F., Latourette, H.B. and Meigs, J.W. (1992) Early menopause in long term survivors of cancer during adolescence. Am. J. Obstet. Gynecol., 166, 788-793.
9. Cook, C.L., Siow, Y., Taylor, S. and Fallat, M.E. (2000) Serum mullerian inhibiting substance levels during normal menstrual cycles. Fertil. Steril., 73, 859-861.
10. Creus, M., Penarrubia, J., Fabregues, F., Vidal, E., Carmona, F., Casamitjana, R., Vanrell, J.A. and Balasch, J. (2000) Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome. Hum. Reprod., 15, 2341-2346.
11. Critchley, H.O., Wallace, W.H., Shalet, S.M., Mamtora, H., Higginson, J. and Anderson, D.C. (1992) Abdominal irradiation in childhood: The potential for pregnancy. Br. J. Obstet. Gynaecol., 99, 392-394.
12. De Vet, A., Laven, J.S., De Jong, F.H., Themmen, A.P. and Fauser, B.C. (2002) Antimullerian hormone serum levels: A putative marker for ovarian aging. Fertil. Steril., 77, 357-362.
13. Dumesic, D.A., Damario, M.A., Session, D.R., Famuyide, A., Lesnick, T.G., Thornhill, A.R. and McNeilly, A.S. (2001) Ovarian morphology and serum hormone markers as predictors of ovarian follicle recruitment by gonadotrophins for in vitro fertilisation. J. Clin. Endocrinol. Metab., 86, 2538-2543.
14. Durlinger, A.L., Kramer, P., Karels, B., De Jong, F.H., Uilenbroek, J.T., Grootegoed, J.A. et al. (1999) Control of primordial follicle recruitment by anti-mullerian hormone in the mouse ovary. Endocrinology, 140, 5789-5796.
15. Faddy, M.J., Gosden, R.G., Gougeon, A., Richardson, S.J. and Nelson, J.F. (1992) Accelerated disappearance of ovarian follicles in mid-life; Implications for forecasting menopause. Hum. Reprod., 7, 1342-1346.
16. Fanchin, R., Schonauer, L.M., Righini, C., Frydman, N., Frydman, R. and Taieb, J. (2003a) Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum. Reprod., 18, 328-332.
17. Fanchin, R., Schonauer, L.M., Righini, C., Guibourdenche, J., Frydman, R. and Taieb, J. (2003b) Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum. Reprod., 18, 323-327.
18. Gougeon, A., Echochard, R. and Thalabard, J.C. (1994) Age-related changes of the population of human ovarian follicles: Increase in the disappearance rate of non-growing and early-growing follicles in aging women. Biol. Reprod., 50, 653-663.
19. Himelstein-Braw, R., Peters, H. and Faber, M. (1978) Morphological study of the ovaries of leukaemic children. Br. J. Cancer, 38, 82-87.
20. Larsen, E.C., Muller, J., Rechnitzer, C., Schiegelow, K. and Nyboe Anderson, A. (2003) Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH < 10 IU/l. Hum. Reprod., 18, 417-422.
21. Mackie, E.J., Radford, M., and Shalet, S.M. (1996) Gonadal function following chemotherapy for childhood Hodgkin's disease. Med. Pediatr. Oncol., 27, 74-78.
22. Mertens, A.C., Yasui, Y., Neglia, J.P., Potter, J.D., Nesbit, M.E., Jr., Ruccione, K., Smithson, W.A. and Robinson, L.L. (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J. Clin. Oncol., 19, 3163-3172.
23. Sanders, J.E., Hawley, J., Levy, W., Gooley, T., Buckner, C.D., Deeg, H.J., Doney, K., Storb, R., Sullivan, K., Witherspoon, R. and Appelbaum, F.R. (1996) Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood, 87, 3045-3052.
24. Scheffer, G.J., Broekmans, F.J., Dorland, M., Habbema, J.D., Looman, C.W. and Te Velde, E.R. (1999) Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil. Steril., 72, 845-851.
25. Scheffer, G.J., Broekmans, F.J., Looman, C.W., Blankenstein, M., Fauser, B.C., Te Jong, F.H. and Te Velde, E.R. (2003) The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum. Reprod., 18, 700-706.
26. Seifer, D.B., Gardiner, A.C., Lambert-Messerlian, G., Blazer, A.S., Hogan, J.W. and Berk, C.A. (1997) Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil. Steril., 67, 110-114.
27. Seifer, D.B., MacLaughlin, D.T., Christian, B.P., Feng, B. and Shelden, R.M. (2002) Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil. Steril., 77, 468-471.
28. Sherman, B.M., West, J.H. and Korenman, S.G. (1976) The menopausal transition: Analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J. Clin. Endocrinol. Metab., 42, 629-636.
29. Syrop, C.H., Dawson, J.D., Husman, K.J., Husman, K.J., Sparks, A.E. and Van Voorhis, B.J. (1999) Ovarian volume may predict assisted reproductive outcomes better than follicle stimulating hormone concentration on day 3. Hum. Reprod., 14, 1752-1756.
30. Tilly, J.L. and Kolesnick, R.N. (2002) Sphingolipids, apoptosis, cancer treatments and the ovary: Investigating a crime against female fertility. Biochim. Biophys. Acta, 1585, 135-138.
31. Tinkanen, H., Blauer, M., Laippala, P., Tuohimaa, P. and Kujansuu, E. (1999) Prognostic factors in controlled ovarian hyperstimulation. Fertil. Steril., 72, 932-936.
32. Tomas, C., Nuojua-Huttunen, S. and Martikainen, H. (1997) Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization. Hum. Reprod., 12, 220-223.
33. Van Rooij, I.A., Broekmans, F.J., Te Velde, E.R., Fauser, B.C., Bancsi, L.F., Jong, F.H. and Themmen, A.P. (2002) Serum anti-Müllerian hormone levels: A novel measure of ovarian reserve. Hum. Reprod., 17, 3065-3071.
34. Wallace, W.H.B., Shalet, S.M., Crowne, E.C., Morris-Jones, P.H. and Gattamaneni, H.R. (1989a) Ovarian failure following abdominal irradiation in childhood: Natural history and prognosis. Clin. Oncol., 1, 75-79.
35. Wallace, W.H.B., Shalet, S.M., Crowne, E.C., Morris-Jones, P.H., Gattamaneni, H.R. and Price, D.A. (1989b) Gonadal dysfunction due to cisplatin. Med. Pediatr. Oncol., 17, 409-413.
36. Wallace, W.H.B., Shalet, S.M., Tetlow, L.J. and Morris-Jones, P.H. (1993) Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med. Pediatr. Oncol., 21, 333-339.
37. Wallace, W.H.B., Thomson, A.B. and Kelsey, T.W. (2003) The radiosensitivity of the human oocyte. Hum. Reprod., 18, 117-121.
38. Wallach, E.E. (1995) Pitfalls in evaluating the ovarian reserve. Fertil. Steril., 63, 12-14.
39. Whitehead, E., Shalet, S.M., Blackledge, G., Todd, I., Crowther, D. and Beardwell, C.G. (1983) The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer, 52, 988-993.
40. Yong, P.Y.K., Baird, D.T., Thong, K.J., McNeilly, A.S. and Anderson, R.A. (2003) Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation. Hum. Reprod., 18, 35-44.